2024
Hypertension and risk of endometrial cancer: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium (E2C2)
Habeshian T, Peeri N, De Vivo I, Schouten L, Shu X, Cote M, Bertrand K, Chen Y, Clarke M, Clendenen T, Cook L, Costas L, Dal Maso L, Freudenheim J, Friedenreich C, Gallagher G, Gierach G, Goodman M, Jordan S, La Vecchia C, Lacey J, Levi F, Liao L, Lipworth L, Lu L, Matias-Guiu X, Moysich K, Mutter G, Na R, Naduparambil J, Negri E, O'Connell K, O'Mara T, Hernández I, Palmer J, Parazzini F, Patel A, Penney K, Prizment A, Ricceri F, Risch H, Sacerdote C, Sandin S, Stolzenberg-Solomon R, van den Brandt P, Webb P, Wentzensen N, Wijayabahu A, Wilkens L, Xu W, Yu H, Zeleniuch-Jacquotte A, Zheng W, Du M, Setiawan V. Hypertension and risk of endometrial cancer: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium (E2C2). Cancer Epidemiology Biomarkers & Prevention 2024, 33: 788-795. PMID: 38530242, PMCID: PMC11145161, DOI: 10.1158/1055-9965.epi-23-1444.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCase-Control StudiesEndometrial NeoplasmsFemaleHumansHypertensionIncidenceMiddle AgedRisk FactorsConceptsEpidemiology of Endometrial Cancer ConsortiumRisk of endometrial cancerComponents of metabolic syndromeCancer ConsortiumRisk factorsAssociated with endometrial cancer riskIncidence rates of endometrial cancerMultivariable unconditional logistic regression modelStronger magnitude of associationEtiology of endometrial cancerStudy designUnconditional logistic regression modelsIncreased risk of endometrial cancerEndometrial cancer riskRates of endometrial cancerUsers of postmenopausal hormone therapyConfidence intervalsRising prevalence of obesityPrevalence of obesityEndometrial cancerMagnitude of associationEndometrial cancer casesMetabolic syndromeBody mass indexLogistic regression models
2023
Night shift work, sleep duration and endometrial cancer risk: A pooled analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2)
Frias-Gomez J, Alemany L, Benavente Y, Clarke M, de Francisco J, De Vivo I, Du M, Goodman M, Lacey J, Liao L, Lipworth L, Lu L, Merritt M, Michels K, O'Connell K, Paytubi S, Pelegrina B, Peremiquel-Trillas P, Petruzella S, Ponce J, Risch H, Setiawan V, Schouten L, Shu X, Trabert B, Van den Brandt P, Wentzensen N, Wilkens L, Yu H, Costas L. Night shift work, sleep duration and endometrial cancer risk: A pooled analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2). Sleep Medicine Reviews 2023, 72: 101848. PMID: 37716022, PMCID: PMC10840870, DOI: 10.1016/j.smrv.2023.101848.Peer-Reviewed Original ResearchMeSH KeywordsEndometrial NeoplasmsFemaleHumansRisk FactorsShift Work ScheduleSleepSleep DurationWork Schedule ToleranceConceptsNight shift workEndometrial Cancer ConsortiumEndometrial cancer riskEndometrial cancerSleep durationShift workPostmenopausal womenPooled analysisInverse associationOdds ratioCancer riskCancer ConsortiumNon-significant inverse associationStudy-specific odds ratiosEndometrial cancer casesStrong risk factorConfidence intervalsLong sleep durationDaily sleep durationObese womenRisk factorsCancer casesLogistic regressionIndividual dataCancerRisk prediction models for endometrial cancer: development and validation in an international consortium
Shi J, Kraft P, Rosner B, Benavente Y, Black A, Brinton L, Chen C, Clarke M, Cook L, Costas L, Dal Maso L, Freudenheim J, Frias-Gomez J, Friedenreich C, Garcia-Closas M, Goodman M, Johnson L, La Vecchia C, Levi F, Lissowska J, Lu L, McCann S, Moysich K, Negri E, O'Connell K, Parazzini F, Petruzella S, Polesel J, Ponte J, Rebbeck T, Reynolds P, Ricceri F, Risch H, Sacerdote C, Setiawan V, Shu X, Spurdle A, Trabert B, Webb P, Wentzensen N, Wilkens L, Xu W, Yang H, Yu H, Du M, De Vivo I. Risk prediction models for endometrial cancer: development and validation in an international consortium. Journal Of The National Cancer Institute 2023, 115: 552-559. PMID: 36688725, PMCID: PMC10165481, DOI: 10.1093/jnci/djad014.Peer-Reviewed Original ResearchConceptsNurses' Health StudyRisk prediction modelNHS IIEndometrial cancerHealth StudyGenetic factorsEndometrial cancer incidence ratesOvarian Cancer Screening TrialCancer risk prediction modelsEndometrial Cancer ConsortiumPostmenopausal white womenCancer Screening TrialCancer risk stratificationCase-control studyRisk factor distributionCancer incidence ratesRelative risk estimatesEpidemiologic modelHeterogeneous study populationsPublic health practiceProphylactic hysterectomyRisk stratificationEpidemiologic factorsIncidence rateSelect cohort
2022
Dietary omega-3 fatty acids and endometrial cancer risk in the Epidemiology of Endometrial Cancer Consortium: An individual-participant meta-analysis
Brasky T, Hade E, Cohn D, Newton A, Petruzella S, O'Connell K, Bertrand K, Cook L, De Vivo I, Du M, Freudenheim J, Friedenreich C, Goodman M, Gorzelitz J, Ibiebele T, Krogh V, Liao L, Lipworth L, Lu L, McCann S, O'Mara T, Palmer J, Ponte J, Prizment A, Risch H, Sandin S, Schouten L, Setiawan V, Shu X, Trabert B, van den Brandt P, Webb P, Wentzensen N, Wilkens L, Wolk A, Yu H, Neuhouser M. Dietary omega-3 fatty acids and endometrial cancer risk in the Epidemiology of Endometrial Cancer Consortium: An individual-participant meta-analysis. Gynecologic Oncology 2022, 169: 137-146. PMID: 36934308, PMCID: PMC10025515, DOI: 10.1016/j.ygyno.2022.10.015.Peer-Reviewed Original ResearchMeSH KeywordsDietEndometrial NeoplasmsFatty Acids, Omega-3FemaleHumansLogistic ModelsObesityOverweightProspective StudiesRisk FactorsConceptsEndometrial cancer riskEndometrial Cancer ConsortiumHigh dietary intakeCancer riskDietary intakeObese womenOdds ratioCancer ConsortiumDietary omega-3 fatty acidsOmega-3 fatty acidsEnergy-adjusted quartilesEndometrial cancer casesEndometrial cancer incidenceProspective cohort studyFood frequency questionnaireNormal-weight womenFatty acid intakeAdjusted odds ratioBody mass indexLong-chain omega-3Anti-inflammatory propertiesSubgroup of womenConfidence intervalsCase-control studyTwo-stage individual participant data
2019
Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer Consortium
Webb PM, Na R, Weiderpass E, Adami HO, Anderson KE, Bertrand KA, Botteri E, Brasky TM, Brinton LA, Chen C, Doherty JA, Lu L, McCann SE, Moysich KB, Olson S, Petruzella S, Palmer JR, Prizment AE, Schairer C, Setiawan VW, Spurdle AB, Trabert B, Wentzensen N, Wilkens L, Yang HP, Yu H, Risch HA, Jordan SJ. Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer Consortium. Annals Of Oncology 2019, 30: 310-316. PMID: 30566587, PMCID: PMC6386026, DOI: 10.1093/annonc/mdy541.Peer-Reviewed Original ResearchConceptsNon-aspirin nonsteroidal anti-inflammatory drugsNonsteroidal anti-inflammatory drugsEndometrial Cancer ConsortiumEndometrial cancerAnti-inflammatory drugsObese womenOdds ratioCancer ConsortiumStudy-specific odds ratiosLogistic regressionStandard-dose aspirinUse of aspirinUse of acetaminophenConfidence intervalsTimes/weekCase-control studyRisk of cancerMixed-effects logistic regressionLow-dose formulationsLeast weekly useNormal weightPooled analysisInverse associationStratified analysisReduced risk
2018
Identification of nine new susceptibility loci for endometrial cancer
O’Mara T, Glubb DM, Amant F, Annibali D, Ashton K, Attia J, Auer PL, Beckmann MW, Black A, Bolla MK, Brauch H, Brenner H, Brinton L, Buchanan DD, Burwinkel B, Chang-Claude J, Chanock SJ, Chen C, Chen MM, Cheng THT, Clarke CL, Clendenning M, Cook LS, Couch FJ, Cox A, Crous-Bous M, Czene K, Day F, Dennis J, Depreeuw J, Doherty JA, Dörk T, Dowdy SC, Dürst M, Ekici AB, Fasching PA, Fridley BL, Friedenreich CM, Fritschi L, Fung J, García-Closas M, Gaudet MM, Giles GG, Goode EL, Gorman M, Haiman CA, Hall P, Hankison SE, Healey CS, Hein A, Hillemanns P, Hodgson S, Hoivik EA, Holliday EG, Hopper JL, Hunter DJ, Jones A, Krakstad C, Kristensen VN, Lambrechts D, Marchand LL, Liang X, Lindblom A, Lissowska J, Long J, Lu L, Magliocco AM, Martin L, McEvoy M, Meindl A, Michailidou K, Milne RL, Mints M, Montgomery GW, Nassir R, Olsson H, Orlow I, Otton G, Palles C, Perry JRB, Peto J, Pooler L, Prescott J, Proietto T, Rebbeck TR, Risch HA, Rogers PAW, Rübner M, Runnebaum I, Sacerdote C, Sarto GE, Schumacher F, Scott RJ, Setiawan VW, Shah M, Sheng X, Shu XO, Southey MC, Swerdlow AJ, Tham E, Trovik J, Turman C, Tyrer JP, Vachon C, VanDen Berg D, Vanderstichele A, Wang Z, Webb PM, Wentzensen N, Werner HMJ, Winham SJ, Wolk A, Xia L, Xiang YB, Yang HP, Yu H, Zheng W, Pharoah PDP, Dunning AM, Kraft P, De Vivo I, Tomlinson I, Easton DF, Spurdle AB, Thompson DJ. Identification of nine new susceptibility loci for endometrial cancer. Nature Communications 2018, 9: 3166. PMID: 30093612, PMCID: PMC6085317, DOI: 10.1038/s41467-018-05427-7.Peer-Reviewed Original ResearchConceptsGenome-wide association studiesCandidate causal genesCausal genesNovel genome-wide significant lociRisk lociEndometrial cancer risk lociGenome-wide significant lociExpression quantitative trait loci (eQTL) analysisQuantitative trait locus (QTL) analysisSignal transduction proteinsCancer risk lociNew susceptibility lociTransduction proteinsSignificant lociLocus analysisNegative regulatorAssociation studiesFemale reproductive tractSusceptibility lociLoci associateLociGenesDecreased expressionReproductive tractRisk alleles
2017
Breastfeeding and Endometrial Cancer Risk
Jordan SJ, Na R, Johnatty SE, Wise LA, Adami HO, Brinton LA, Chen C, Cook LS, Dal Maso L, De Vivo I, Freudenheim JL, Friedenreich CM, La Vecchia C, McCann SE, Moysich KB, Lu L, Olson SH, Palmer JR, Petruzella S, Pike MC, Rebbeck TR, Ricceri F, Risch HA, Sacerdote C, Setiawan VW, Sponholtz TR, Shu XO, Spurdle AB, Weiderpass E, Wentzensen N, Yang HP, Yu H, Webb PM. Breastfeeding and Endometrial Cancer Risk. Obstetrics And Gynecology 2017, 129: 1059-1067. PMID: 28486362, PMCID: PMC5473170, DOI: 10.1097/aog.0000000000002057.Peer-Reviewed Original ResearchMeSH KeywordsBreast FeedingEndometrial NeoplasmsFemaleGlobal HealthHumansRisk FactorsRisk Reduction BehaviorWomen's HealthConceptsEndometrial cancer riskEndometrial cancerCancer riskOdds ratioStudy-specific odds ratiosEndometrial Cancer ConsortiumBody mass indexMultivariable logistic regressionConfidence intervalsCase-control studyMaternal benefitsNulliparous womenHistologic subtypeMass indexCommon cancerLower riskStudy heterogeneityCancer ConsortiumControl groupCancerLogistic regressionAverage durationLonger average durationWomenBreastfeedingEpidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer
Kim SJ, Rosen B, Fan I, Ivanova A, McLaughlin JR, Risch H, Narod SA, Kotsopoulos J. Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer. British Journal Of Cancer 2017, 116: 964-971. PMID: 28208158, PMCID: PMC5379147, DOI: 10.1038/bjc.2017.35.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdenocarcinoma, MucinousAdultAgedCanadaCystadenocarcinoma, SerousEndometrial NeoplasmsEpidemiologic FactorsFemaleFollow-Up StudiesHormone Replacement TherapyHumansMiddle AgedNeoplasm InvasivenessNeoplasm StagingOvarian NeoplasmsParityPregnancyPrognosisReproductive HistoryYoung AdultConceptsOvarian cancer-specific mortalityCancer-specific mortalityHormone replacement therapyRisk of deathEpithelial ovarian cancerOvarian cancerHazard ratioEpidemiologic factorsOvulatory cyclesOvarian cancer-specific deathOvarian cancer-specific survivalInvasive epithelial ovarian cancerBMI 5 yearsCancer-specific survivalCancer-specific deathOntario Cancer RegistryProportional hazards regressionConfidence intervalsBorderline significant associationOvarian cancer developmentLong-term survivalGreater cumulative numberHRT useCancer RegistryHistologic subtype
2016
Meta-dimensional data integration identifies critical pathways for susceptibility, tumorigenesis and progression of endometrial cancer
Wei R, De Vivo I, Huang S, Zhu X, Risch H, Moore JH, Yu H, Garmire LX. Meta-dimensional data integration identifies critical pathways for susceptibility, tumorigenesis and progression of endometrial cancer. Oncotarget 2016, 7: 55249-55263. PMID: 27409342, PMCID: PMC5342415, DOI: 10.18632/oncotarget.10509.Peer-Reviewed Original ResearchConceptsEndometrial cancerEC riskSusceptible pathwaysCancer Genome Atlas (TCGA) samplesProgression of ECEndometrial Cancer StudyCommon female cancerGenome-wide association studiesEC cohortFemale cancersCell cycle pathwayCancerP53 signalingCommon pathwayGenetic polymorphismsCancer studiesSurvival dataProgressionCritical pathwaysGenetic information processing pathwaysMulti-omics analysisTumorigenesisCycle pathwayMetabolism pathwaysRiskGWAS meta-analysis of 16 852 women identifies new susceptibility locus for endometrial cancer
Chen MM, O'Mara TA, Thompson DJ, Painter JN, Group T, Attia J, Black A, Brinton L, Chanock S, Chen C, Cheng T, Cook L, Crous-Bou M, Doherty J, Friedenreich C, Garcia-Closas M, Gaudet M, Gorman M, Haiman C, Hankinson S, Hartge P, Henderson B, Hodgson S, Holliday E, Horn-Ross P, Hunter D, Le Marchand L, Liang X, Lissowska J, Long J, Lu L, Magliocco A, Martin L, McEvoy M, Group S, Olson S, Orlow I, Pooler L, Prescott J, Rastogi R, Rebbeck T, Risch H, Sacerdote C, Schumacher F, Setiawan V, Scott R, Sheng X, Shu X, Turman C, Van Den Berg D, Wang Z, Weiss N, Wentzensen N, Xia L, Xiang Y, Yang H, Yu H, Zheng W, Pharoah P, Dunning A, Tomlinson I, Easton D, Kraft P, Spurdle A, De Vivo I. GWAS meta-analysis of 16 852 women identifies new susceptibility locus for endometrial cancer. Human Molecular Genetics 2016, 25: 2612-2620. PMID: 27008869, PMCID: PMC5868213, DOI: 10.1093/hmg/ddw092.Peer-Reviewed Original ResearchConceptsEndometrial cancerCommon gynecological malignancyMeta-analysis resultsGynecological malignanciesGenome-wide significanceGenetic predispositionWide association studyNew susceptibility lociGenetic susceptibilityGenetic riskCancerNew lociAssociation studiesEuropean ancestrySusceptibility lociWomen
2015
Body Mass Index Genetic Risk Score and Endometrial Cancer Risk
Prescott J, Setiawan VW, Wentzensen N, Schumacher F, Yu H, Delahanty R, Bernstein L, Chanock SJ, Chen C, Cook LS, Friedenreich C, Garcia-Closas M, Haiman CA, Le Marchand L, Liang X, Lissowska J, Lu L, Magliocco AM, Olson SH, Risch HA, Shu XO, Ursin G, Yang HP, Kraft P, De Vivo I. Body Mass Index Genetic Risk Score and Endometrial Cancer Risk. PLOS ONE 2015, 10: e0143256. PMID: 26606540, PMCID: PMC4659592, DOI: 10.1371/journal.pone.0143256.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskBody mass indexGenotype risk scoreCancer riskRisk scoreHigher body mass indexRisk allelesIndependent risk factorEndometrial cancer casesExcess body weightRisk factor dataGenetic risk scoreGenome-wide association studiesEndometrial cancerMass indexBMI riskRisk factorsEffect modificationCancer casesRisk lociBody weightCancer shareExploratory analysisStudy designControl participantsJoint Effect of Genotypic and Phenotypic Features of Reproductive Factors on Endometrial Cancer Risk
Wang Z, Risch H, Lu L, Irwin ML, Mayne S, Schwartz P, Rutherford T, De Vivo I, Yu H. Joint Effect of Genotypic and Phenotypic Features of Reproductive Factors on Endometrial Cancer Risk. Scientific Reports 2015, 5: 15582. PMID: 26498156, PMCID: PMC4620445, DOI: 10.1038/srep15582.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskEndometrial cancerCancer riskEstrogen exposureEndometrial cancer patientsTime of studyGenetic risk scorePotential confoundersCancer patientsMenstrual cycleReproductive factorsRisk scorePossible markerMajor causeCancerMenopauseObesityPhenotypic featuresRiskPopulation controlsAgeMenarcheWomenExposureTNMCInfertility and incident endometrial cancer risk: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2)
Yang HP, Cook LS, Weiderpass E, Adami HO, Anderson KE, Cai H, Cerhan JR, Clendenen TV, Felix AS, Friedenreich CM, Garcia-Closas M, Goodman MT, Liang X, Lissowska J, Lu L, Magliocco AM, McCann SE, Moysich KB, Olson SH, Petruzella S, Pike MC, Polidoro S, Ricceri F, Risch HA, Sacerdote C, Setiawan VW, Shu XO, Spurdle AB, Trabert B, Webb PM, Wentzensen N, Xiang YB, Xu Y, Yu H, Zeleniuch-Jacquotte A, Brinton LA. Infertility and incident endometrial cancer risk: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2). British Journal Of Cancer 2015, 112: 925-933. PMID: 25688738, PMCID: PMC4453954, DOI: 10.1038/bjc.2015.24.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCohort StudiesEndometrial NeoplasmsFemaleHumansInfertility, FemaleLogistic ModelsMiddle AgedParityRisk FactorsSelf ReportConceptsEndometrial cancer riskCancer riskInfertility causesOdds ratioElevated endometrial cancer riskEndometrial cancer risk factorsEndometrial Cancer ConsortiumSelf-reported infertilityAdjusted odds ratioCancer risk factorsConfidence intervalsCase-control studyStudy-specific definitionsParous womenEndometrial cancerNulliparous womenPooled analysisNational registryRisk factorsCancer ConsortiumInfertilityNulliparityInfertility concernsInfertility dataLarger study
2014
Intrauterine devices and endometrial cancer risk: A pooled analysis of the Epidemiology of Endometrial Cancer Consortium
Felix AS, Gaudet MM, La Vecchia C, Nagle CM, Shu XO, Weiderpass E, Adami HO, Beresford S, Bernstein L, Chen C, Cook LS, De Vivo I, Doherty JA, Friedenreich CM, Gapstur SM, Hill D, Horn‐Ross P, Lacey JV, Levi F, Liang X, Lu L, Magliocco A, McCann SE, Negri E, Olson SH, Palmer JR, Patel AV, Petruzella S, Prescott J, Risch HA, Rosenberg L, Sherman ME, Spurdle AB, Webb PM, Wise LA, Xiang Y, Xu W, Yang HP, Yu H, Zeleniuch‐Jacquotte A, Brinton LA. Intrauterine devices and endometrial cancer risk: A pooled analysis of the Epidemiology of Endometrial Cancer Consortium. International Journal Of Cancer 2014, 136: e410-e422. PMID: 25242594, PMCID: PMC4267918, DOI: 10.1002/ijc.29229.Peer-Reviewed Original ResearchConceptsEndometrial Cancer ConsortiumEndometrial cancer riskIntrauterine deviceEC riskPooled analysisCancer riskLast useCancer ConsortiumOlder ageUse of IUDsMultivariable logistic regressionConfidence intervalsPooled odds ratioCase-control studyInert intrauterine deviceDuration of useHeavy bleedingOdds ratioReversible contraceptivesHormonal changesEC casesReduced riskBiologic effectsUterine environmentLogistic regressionCross-cancer pleiotropic analysis of endometrial cancer: PAGE and E2C2 consortia
Setiawan VW, Schumacher F, Prescott J, Haessler J, Malinowski J, Wentzensen N, Yang H, Chanock S, Brinton L, Hartge P, Lissowska J, Park SL, Cheng I, Bush WS, Crawford DC, Ursin G, Horn-Ross P, Bernstein L, Lu L, Risch H, Yu H, Sakoda LC, Doherty J, Chen C, Jackson R, Yasmeen S, Cote M, Kocarnik JM, Peters U, Kraft P, De Vivo I, Haiman CA, Kooperberg C, Le Marchand L. Cross-cancer pleiotropic analysis of endometrial cancer: PAGE and E2C2 consortia. Carcinogenesis 2014, 35: 2068-2073. PMID: 24832084, PMCID: PMC4146418, DOI: 10.1093/carcin/bgu107.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskEndometrial cancerCancer riskSingle nucleotide polymorphismsEndometrial Cancer ConsortiumEndometrial cancer casesBody mass indexProstate cancer riskMultiple cancer sitesEvidence of heterogeneityMass indexCancer sitesProstate cancerBonferroni-corrected P valueCancer casesCancer-associated single nucleotide polymorphismsCancer ConsortiumGenome-wide association studiesCancerStatistical significanceP-valueEpidemiologyRiskBiological mechanismsEuropean ancestryExome-Wide Association Study of Endometrial Cancer in a Multiethnic Population
Chen MM, Crous-Bou M, Setiawan VW, Prescott J, Olson SH, Wentzensen N, Black A, Brinton L, Chen C, Chen C, Cook LS, Doherty J, Friedenreich CM, Hankinson SE, Hartge P, Henderson BE, Hunter DJ, Le Marchand L, Liang X, Lissowska J, Lu L, Orlow I, Petruzella S, Polidoro S, Pooler L, Rebbeck TR, Risch H, Sacerdote C, Schumacher F, Sheng X, Shu XO, Weiss NS, Xia L, Van Den Berg D, Yang HP, Yu H, Chanock S, Haiman C, Kraft P, De Vivo I. Exome-Wide Association Study of Endometrial Cancer in a Multiethnic Population. PLOS ONE 2014, 9: e97045. PMID: 24810602, PMCID: PMC4014590, DOI: 10.1371/journal.pone.0097045.Peer-Reviewed Original ResearchMeSH KeywordsAgedEndometrial NeoplasmsExomeFemaleGene FrequencyGenetic Predisposition to DiseaseGenetic VariationGenome-Wide Association StudyHumansMiddle AgedConceptsGenome-wide association studiesExome-wide association studyAssociation studiesPrevious genome-wide association studyRare genetic variantsRare variantsHumanExome BeadChipGenetic variantsCommon variantsEndometrial cancerEC riskGenetic factorsEC pathogenesisGlobal significanceVariantsMultiethnic populationRisk of ECBeadChipEndometrial Cancer ConsortiumLociLarge effectCancer morbidityRisk factorsRisk Factors for Ovarian Cancers With and Without Microsatellite Instability
Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, Zhang S, Sun P, Narod SA, Schildkraut J. Risk Factors for Ovarian Cancers With and Without Microsatellite Instability. International Journal Of Gynecological Cancer 2014, 24: 664-669. PMID: 24755492, DOI: 10.1097/igc.0000000000000134.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdenocarcinoma, MucinousBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsCanadaCystadenocarcinoma, SerousDNA, NeoplasmEndometrial NeoplasmsFemaleGenetic Predisposition to DiseaseHumansMicrosatellite InstabilityMicrosatellite RepeatsMiddle AgedMutationNeoplasm StagingOvarian NeoplasmsPrognosisRisk FactorsSyndromeUnited StatesConceptsOvarian cancer patientsOral contraceptive useBody mass indexEpithelial ovarian cancerOvarian cancerCancer patientsHistologic subtypeMass indexTubal ligationRisk factorsBRCA2 mutationsContraceptive usePast oral contraceptive usePrimary epithelial ovarian cancerOvarian cancer risk factorsBRCA1 mutationsNational Cancer Institute criteriaProtective factorsSpecific histologic subtypesCancer risk factorsPopulation-based studyMSI-high cancersCases of cancerMSI-high tumorsBRCA2 mutation status
2013
Genome-wide association study of endometrial cancer in E2C2
De Vivo I, Prescott J, Setiawan VW, Olson SH, Wentzensen N, The Australian National Endometrial Cancer Study Group, Attia J, Black A, Brinton L, Chen C, Chen C, Cook LS, Crous-Bou M, Doherty J, Dunning AM, Easton DF, Friedenreich CM, Garcia-Closas M, Gaudet MM, Haiman C, Hankinson SE, Hartge P, Henderson BE, Holliday E, Horn-Ross PL, Hunter DJ, Le Marchand L, Liang X, Lissowska J, Long J, Lu L, Magliocco AM, McEvoy M, O’Mara T, Orlow I, Painter JN, Pooler L, Rastogi R, Rebbeck TR, Risch H, Sacerdote C, Schumacher F, Scott RJ, Sheng X, Shu XO, Spurdle AB, Thompson D, VanDen Berg D, Weiss NS, Xia L, Xiang YB, Yang HP, Yu H, Zheng W, Chanock S, Kraft P. Genome-wide association study of endometrial cancer in E2C2. Human Genetics 2013, 133: 211-224. PMID: 24096698, PMCID: PMC3898362, DOI: 10.1007/s00439-013-1369-1.Peer-Reviewed Original ResearchMeSH KeywordsAgedAsian PeopleBlack or African AmericanCase-Control StudiesCohort StudiesEndometrial NeoplasmsFemaleGenetic LociGenetic Predisposition to DiseaseGenome-Wide Association StudyHepatocyte Nuclear Factor 1-betaHumansMiddle AgedPolymorphism, Single NucleotideRisk FactorsUnited StatesWhite PeopleConceptsGenome-wide association studiesSingle nucleotide polymorphismsTwo-stage genome-wide association studyAssociation studiesGenome-wide significanceIndependent single nucleotide polymorphismsNovel genetic polymorphismsHNF1B locusGenetic markersEuropean ancestryNovel variantsGenetic polymorphismsGenetic factorsEC susceptibilityPolymorphismLociCommon gynecological malignancyE2C2AncestryReplicationCancerVariantsType I and II Endometrial Cancers: Have They Different Risk Factors?
Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, Wolk A, Wentzensen N, Weiss NS, Webb PM, van den Brandt PA, van de Vijver K, Thompson PJ, Group T, Strom BL, Spurdle AB, Soslow RA, Shu XO, Schairer C, Sacerdote C, Rohan TE, Robien K, Risch HA, Ricceri F, Rebbeck TR, Rastogi R, Prescott J, Polidoro S, Park Y, Olson SH, Moysich KB, Miller AB, McCullough ML, Matsuno RK, Magliocco AM, Lurie G, Lu L, Lissowska J, Liang X, Lacey JV, Kolonel LN, Henderson BE, Hankinson SE, Håkansson N, Goodman MT, Gaudet MM, Garcia-Closas M, Friedenreich CM, Freudenheim JL, Doherty J, De Vivo I, Courneya KS, Cook LS, Chen C, Cerhan JR, Cai H, Brinton LA, Bernstein L, Anderson KE, Anton-Culver H, Schouten LJ, Horn-Ross PL. Type I and II Endometrial Cancers: Have They Different Risk Factors? Journal Of Clinical Oncology 2013, 31: 2607-2618. PMID: 23733771, PMCID: PMC3699726, DOI: 10.1200/jco.2012.48.2596.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAge FactorsAgedBiopsy, NeedleCarcinoma, EndometrioidCase-Control StudiesCohort StudiesConfidence IntervalsContraceptives, OralDatabases, FactualDiabetes MellitusDisease-Free SurvivalEndometrial NeoplasmsFemaleHumansImmunohistochemistryMiddle AgedNeoplasm InvasivenessNeoplasm StagingObesityOdds RatioRisk FactorsSensitivity and SpecificitySmokingSurvival AnalysisConceptsType II tumorsII tumorsRisk factorsEndometrial cancerOdds ratioHigh-grade endometrioid tumorsEndometrial cancer risk factorsType IEndometrial Cancer ConsortiumEndometrial cancer typesType I tumorsEndometrial cancer casesOral contraceptive useRisk factor patternsBody mass indexCancer risk factorsCommon etiologic factorCase-control studyDifferent risk factorsEndometrioid tumorsI tumorsMass indexCigarette smokingPooled analysisEtiologic factorsRisk Factors for Ovarian Cancers With and Without Microsatellite Instability
Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, Zhang S, Ping S, Narod SA, Schildkraut J. Risk Factors for Ovarian Cancers With and Without Microsatellite Instability. International Journal Of Gynecological Cancer 2013, 23: 1010. PMID: 23748177, PMCID: PMC3740723, DOI: 10.1097/igc.0b013e31829a5527.Peer-Reviewed Original ResearchConceptsOvarian cancer patientsOral contraceptive useBody mass indexEpithelial ovarian cancerOvarian cancerCancer patientsHistologic subtypeMass indexHistologic findingsTubal ligationRisk factorsContraceptive usePast oral contraceptive usePrimary epithelial ovarian cancerOvarian cancer risk factorsBRCA1 mutationsNational Cancer Institute criteriaProtective factorsDifferent histologic findingsSpecific histologic subtypesCancer risk factorsPopulation-based studyMSI-high cancersMSI-high tumorsBRCA2 mutation status